Released Aug 7, 2018, after the close
10-Q filed Aug 7, 2018, 38 days after period end · 0001193125-18-241301
Q2 2018 · 10-Q
Revenue$19.89M$19.89M +662,933.3% vs Q2 2017+98.9% vs Q1 2018
Net Income-$33.66M-$33.66M N/M vs Q2 2017N/M vs Q1 2018
EPS Diluted-$0.60-$0.60 N/M vs Q2 2017N/M vs Q1 2018
Operating Income-$34,332,000N/M
Operating Cash Flowderived-$37,628,000N/M
Free Cash Flowderived-$38,025,000—
Margins · derived
Operating margin-172.6%+991560.7 pt vs Q2 2017
Net margin-169.2%+979397.5 pt vs Q2 2017
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2018 | Q2 2017 | Q2 2016 | Q2 2015 |
|---|---|---|---|---|
| Revenue | $19.89M | $3.00K | $59.00K | $150.00K |
| Net Income | -$33.66M | -$29.39M | -$30.16M | -$32.70M |
| EPS Diluted | -$0.60 | -$0.64 | -$0.84 | -$0.92 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Karyopharm Therapeutics Inc. · CIK 1503802 · Engraved from SEC EDGAR